论文部分内容阅读
目的观察厄贝沙坦氢氯噻嗪复方片剂治疗原发性高血压的有效性和安全性。方法原发性高血压80例,继发性高血压,严重肝、肾功能不全者除外,服用厄贝沙坦氢氯噻嗪,疗程12周。结果 80例中显效48例(60.0%),有效27例(33.75%),无效5例(6.25%),总有效率93.75%,治疗后与治疗前比较,血压明显下降,治疗前为(160±12/100±10)mmHg,治疗后为(130±10/82±10)mmHg。检测24h动态血压,计算降压谷峰比值率>65%。结论厄贝沙坦氢氯噻嗪治疗原发性高血压安全有效,患者依从性好。
Objective To observe the efficacy and safety of Irbesartan Hydrochlorothiazide Compound Tablet in the treatment of essential hypertension. Methods 80 cases of essential hypertension except secondary hypertension, severe liver and renal insufficiency, taking irbesartan hydrochlorothiazide for 12 weeks. Results In 80 cases, 48 cases (60.0%) were markedly effective, 27 cases (33.75%) were effective, 5 cases (6.25%) were ineffective and the total effective rate was 93.75%. After treatment, the blood pressure decreased obviously ± 12/100 ± 10) mmHg and (130 ± 10/82 ± 10) mmHg after treatment. 24h ambulatory blood pressure was measured, calculated trough peak ratio> 65%. Conclusion Irbesartan hydrochlorothiazide treatment of essential hypertension safe and effective, patient compliance is good.